ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues.Frontiers in immunology · 2025Pooled it
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.Nature medicine · 2024Trial
- ΔAverage of long and short axis diameter on non-contrast CT is associated with major pathological response to neoadjuvant immunotherapy in resectable non-small cell lung cancer.European radiology · 2026Article
- Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.Translational lung cancer research · 2026Article
- An Observational Study Evaluating the Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients Undergoing Surgery for Non-Small Cell Lung Cancer.Thoracic cancer · 2025Observational
- A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study.Frontiers in oncology · 2024Article
- Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.European radiology · 2023Article
- Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.Biomarker research · 2023Review
- Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity.Frontiers in oncology · 2023Review
- Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer.Clinical Medicine Insights. Oncology · 2023Review
- Immune-based therapies in penile cancer.Nature reviews. Urology · 2022Review
- Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.Journal of translational medicine · 2022Article
- Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research.Frontiers in oncology · 2022Review
- Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis.Frontiers in immunology · 2022Article
- The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.Frontiers in immunology · 2022Review
- Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?Current oncology (Toronto, Ont.) · 2021Review
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.Nature reviews. Clinical oncology · 2021Review
- Multiplex Immunofluorescence Tyramide Signal Amplification for Immune Cell Profiling of Paraffin-Embedded Tumor Tissues.Frontiers in molecular biosciences · 2021Review
- Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.Translational lung cancer research · 2021Review
- Cushing's Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat.Case reports in oncologyArticle
Corrections and comments
- Commented on by
- Comment on
Authors and funding
27 authors at 1 institution in 2 countries.
Funding
Abstract
purposeNintedanib enhances the activity of chemotherapy in metastatic non-small cell lung cancer (NSCLC). In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. PATIENTS AND
methodsEligible patients had stage IB (≥4 cm)-IIIA resectable NSCLC. A safety run-in phase was followed by an expansion phase with nintedanib 200 mg orally twice a day (28 days), followed by three cycles of cisplatin (75 mg/m
resultsTwenty-one patients (stages I/II/III,
conclusionsAlthough tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls. Additional studies of the combination in this setting are not recommended. Posttreatment levels of tumor-infiltrating T cells were associated with patient survival. Use of MPR facilitates the rapid evaluation of neoadjuvant therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.